We are proud to announce our participation in a Series A extension round of https://www.zafrens.com/, a pioneering drug discovery company based in San Diego, California.
Revolutionizing drug discovery through ultra-high throughput screening
Zafrens' Z-Screen™ platform represents a paradigm shift in drug discovery, enabling unprecedented speed and precision in therapeutic development. The platform can create and test hundreds of thousands of different potential medicines in one integrated workflow, which is orders of magnitude larger than the state-of-the-art. This unique capability dramatically accelerates the early phases of drug discovery while significantly reducing costs.
Furthermore, the scale and precision of Zafrens' platform create unique opportunities for generating high-quality data that can be used to train and develop next-generation AI-based drug discovery models. The platform's versatility has been validated through successful pilot collaborations with leading pharmaceutical and biotech companies across multiple medicine classes.
We are excited about Zafrens' potential to transform the drug discovery landscape by combining ultra-high throughput screening capabilities with advanced AI applications. By being able to create and test hundreds of thousands of potential medicines simultaneously and better understanding how they affect cells, Zafrens is able to identify the most promising medicines faster and with greater confidence in their safety. This means that potentially life-changing medicines can be brought to patients more quickly and efficiently.
You can read the full press release on PR Newswire.